Salute e Benessere
Uveitis Treatment Market Size is Estimated at $1.4 Billion by 2034, Growing at a 7% CAGR, Says Fact.MR
Advanced treatment methods, which include biodegradable microspheres and intravitreal implants, provide significant advantages since they directly administer prolonged pharmaceutical exposure to the affected eye tissues. Reducing the need for repeated injections or systemic medications lowers the risk of undesirable systemic effects while increasing patient compliance and convenience.
The rising incidence of uveitis in some countries due to the increasing aging population, a rise in the prevalence of autoimmune disorders, and a focus on improving diagnostic capabilities are major aspects driving the growth of the market for uveitis treatment. Increased funding from pharmaceutical companies and organizations for research and development initiatives aimed at uveitis treatment is driving the exploration of new medicinal agents and treatment strategies.
says a Fact.MR analyst.
Key players in the uveitis treatment industry are Sun Pharmaceutical Industries Ltd., EyePoint Pharmaceuticals, Inc., Ophthotech Corporation, Regeneron Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Inflammasome Therapeutics Inc., Graybug Vision, Inc., TopiVert Pharma Ltd., Pfizer Inc., Bausch Health Companies Inc.
Hospital pharmacies are generating substantial revenue compared to other distribution channels such as retail pharmacies, online pharmacies, and drug stores. Hospital pharmacies face a constant need for uveitis medications since uveitis is a fairly common condition that requires ongoing care and because hospitals often have a big patient base.
Hospitals benefit financially from treating an increasing number of uveitis patients who require continuous access to the prescribed medications. Hospital pharmacies benefit from discounted rates on these medications due to contracts with specific suppliers of uveitis medications.
:
Fact.MR, in its new offering, presents an unbiased analysis of the uveitis treatment market, presenting historical demand data (2019 to 2023) and forecast statistics for 2024 to 2034.
The study divulges essential insights into the market based on treatment (corticosteroids, immunosuppressants, monoclonal antibodies, cycloplegic agents, antibiotics, antivirals, antifungals, analgesics), disease (anterior uveitis, posterior uveitis, intermediate uveitis, panuveitis), cause (infectious uveitis, non-infectious uveitis), and distribution channel (hospital pharmacies, retail pharmacies, online pharmacies, drug stores), across seven major regions of the world ( North America , Western Europe , Eastern Europe , East Asia , Latin America , South Asia & Pacific, and MEA).
stands at US$ 1.9 billion in 2023 and is forecasted to reach US$ 3.5 billion by the end of 2033, increasing at a CAGR of 6.2%.
is anticipated to be worth US$ 4,027.2 million in 2024 and is expected to expand to an astounding size of US$ 10,961.2 million by 2034.
is projected to expand at a stellar CAGR of over 8.5% and is anticipated to grow 2.3x between 2018 and 2028.
is valued at US$ 38 billion in 2023 and is thus anticipated to reach US$ 72 billion by 2033.
is poised to flourish at a CAGR of 8.2% to reach a value of US$ 39 Billion by 2032.
is predicted to accelerate at a CAGR of 5.6% and reach a market valuation of US$ 2.56 billion by the end of 2033.
is a distinguished market research company renowned for its comprehensive market reports and invaluable business insights. As a prominent player in business intelligence, we deliver deep analysis, uncovering market trends, growth paths, and competitive landscapes. Renowned for its commitment to accuracy and reliability, we empower businesses with crucial data and strategic recommendations, facilitating informed decision-making and enhancing market positioning.
With its unwavering dedication to providing reliable market intelligence, FACT.MR continues to assist companies in navigating dynamic market challenges with confidence and achieving long-term success. With a global presence and a team of experienced analysts, FACT.MR ensures its clients receive actionable insights to capitalize on emerging opportunities and stay competitive.
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
: sales@factmr.com
LinkedIn | Twitter | Blog
View original content: https://www.prnewswire.co.uk/news-releases/uveitis-treatment-market-size-is-estimated-at-1-4-billion-by-2034--growing-at-a-7-cagr-says-factmr-302194715.html